-
公开(公告)号：US10407490B2
公开(公告)日：2019-09-10
申请号：US15568830
申请日：2016-04-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mark R. Krystal , David L. Wensel , Jonathan Davis
IPC: A61K38/00 , A61P31/18 , C07K14/78 , A61K47/60 , C07K14/79 , C07K14/005 , C07K14/765
Abstract: The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.
-
公开(公告)号：US11408093B2
公开(公告)日：2022-08-09
申请号：US16813094
申请日：2020-03-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
IPC: C40B40/08 , C07K16/24 , C07K16/28 , C07K14/78 , C07K14/47 , G01N33/68 , C12N15/10 , C40B40/10 , A61K38/00
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US20130196871A1
公开(公告)日：2013-08-01
申请号：US13757664
申请日：2013-02-01
Applicant: Bristol-Myers Squibb Company
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US10464995B2
公开(公告)日：2019-11-05
申请号：US15237484
申请日：2016-08-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US09522951B2
公开(公告)日：2016-12-20
申请号：US14355155
申请日：2012-10-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
Abstract translation: 提供了具有与降低的免疫原性相关的新颖设计的纤连蛋白III型（10Fn3）结合结构域。 本申请描述了替代的10Fn3结合结构域，其中当产生粘合剂时，某些免疫原性区域不被修饰，以便由宿主生物保持识别为自身抗原。 该应用还描述了其中HLA锚定区已经被破坏的10Fn3结合结构域，从而降低相邻区域的免疫原性贡献。 还提供了10Fn3结构域，其具有可以高亲和力结合所需靶的修饰区域的新颖组合。
-
Patent Agency Ranking
公开(公告)号：US20150051149A1
公开(公告)日：2015-02-19
申请号：US14355155
申请日：2012-10-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
IPC: C07K14/78
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
Abstract translation: 提供了具有与降低的免疫原性相关的新颖设计的纤连蛋白III型（10Fn3）结合结构域。 本申请描述了替代的10Fn3结合结构域，其中当产生粘合剂时，某些免疫原性区域不被修饰，以便由宿主生物保持识别为自身抗原。 该应用还描述了其中HLA锚定区已经被破坏的10Fn3结合结构域，从而降低相邻区域的免疫原性贡献。 还提供了10Fn3结构域，其具有可以高亲和力结合所需靶的修饰区域的新颖组合。
-
公开(公告)号：US10604556B2
公开(公告)日：2020-03-31
申请号：US15341623
申请日：2016-11-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US10442851B2
公开(公告)日：2019-10-15
申请号：US15127166
申请日：2015-03-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tracy S. Mitchell , Michael L. Gosselin , Dasa Lipovsek , Rex Parker , Ray Camphausen , Jonathan Davis , David Fabrizio
Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号：US09765132B2
公开(公告)日：2017-09-19
申请号：US13757668
申请日：2013-02-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US11279751B2
公开(公告)日：2022-03-22
申请号：US16581877
申请日：2019-09-25
Applicant: Bristol-Myers Squibb Company
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.029 seconds)
